STOCK TITAN

Elanco Animal Health Incorporated - ELAN STOCK NEWS

Welcome to our dedicated page for Elanco Animal Health Incorporated news (Ticker: ELAN), a resource for investors and traders seeking the latest updates and insights on Elanco Animal Health Incorporated stock.

Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health, committed to innovating and delivering products and services to improve the health and wellness of both farm animals and pets. Established with nearly 70 years of heritage, Elanco operates in over 90 countries with a diverse portfolio of approximately 200 brands. Their core mission is encapsulated in their vision: 'Food and Companionship Enriching Life,' which they pursue through three primary avenues:

  • Enhancing food security by improving the health and productivity of farm animals, thereby contributing to a safer, more affordable, and abundant food supply.
  • Helping pets live longer, healthier lives through advanced veterinary products.
  • Improving food safety standards globally.

Elanco’s dedication to animal health is reflected in their continuous innovation and quality systems, driven by a shared vision of enhancing life for animals and humans alike. This commitment is evident in their recent achievements and ongoing projects. For instance, Elanco's collaboration with Agtech company, Cattler, aims to provide data-driven solutions to cattle farmers, enhancing operational efficiency and productivity through services like Benchmark™ and Experior™.

Elanco's financial health is strong, with the company reporting consistent revenue growth and strategic investments aimed at future expansion. In their recent financial results, Elanco posted a 5% growth in the fourth quarter and strengthened their commercial infrastructure to support ongoing and future growth. They also announced the divestiture of their aqua business to streamline operations and focus on core areas, which is expected to reduce their debt leverage significantly by year-end.

Environmental sustainability is another critical focus for Elanco. Their recent partnership with Athian to create a livestock carbon insetting marketplace is a significant step towards reducing greenhouse gas emissions in the dairy and beef industries. Products like Bovaer®, which significantly reduce methane emissions from cattle, exemplify Elanco's commitment to sustainable farming practices.

Overall, Elanco continues to be at the forefront of animal health innovation, with substantial investments in R&D, strategic partnerships, and a clear commitment to sustainability and community health.

Rhea-AI Summary

Elanco Animal Health (NYSE: ELAN) held its Investor Day today, showcasing an enhanced Innovation, Portfolio, Productivity (IPP) strategy aimed at achieving revenue growth targets. CEO Jeff Simmons emphasized planned annual revenue growth of 3%-4% and adjusted EBITDA and EPS growth. Key highlights include eight expected product launches in 2021, projected revenue additions of $80-150 million, and $300 million in synergies from the Bayer acquisition by 2023. The company raised Q4 2020 revenue guidance to $1,040-$1,070 million, and provided 2021 guidance of $4,520-$4,600 million, despite facing a $70-$75 million impact from antitrust divestitures.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.35%
Tags
none
-
Rhea-AI Summary

Elanco Animal Health has appointed William F. Doyle, alongside Scott Ferguson and Paul Herendeen, to its Board of Directors. This expansion is part of a strategic move to enhance innovation and operational oversight, particularly following the Bayer Animal Health acquisition. The company will also establish a new Innovation, Science and Technology Committee and an independent Advisory Board to bolster R&D efforts. The Finance Committee's role was expanded to focus on operational initiatives and financial oversight, underlining Elanco's commitment to shareholder value creation amidst integration challenges.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.35%
Tags
management
-
Rhea-AI Summary

Kindred Biosciences, Inc. (NASDAQ: KIN) announced a partnership granting Elanco Animal Health exclusive global rights to its monoclonal antibody, KIND-030, targeting canine parvovirus (CPV). KindredBio will receive an upfront payment of $500,000 and potential milestone payments totaling $16 million for development and $94 million in sales milestones. Currently, there are no approved treatments for CPV, which affects about 250,000 dogs annually in the U.S. This collaboration aims to enhance market access for KIND-030.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.52%
Tags
none
Rhea-AI Summary

Elanco Animal Health has agreed to acquire exclusive global rights to KIND-030, a novel monoclonal antibody for treating and preventing canine parvovirus (CPV). This disease affects over 250,000 puppies annually in the U.S. and currently has no approved treatment. The agreement includes a $500,000 upfront payment and potential milestone payments tied to development success. The pivotal efficacy study for the therapeutic indication is expected to conclude in Q1 2021, enhancing Elanco's vaccine and therapeutics portfolio.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.52%
Tags
none
-
Rhea-AI Summary

Elanco Animal Health (NYSE: ELAN) has chosen Indianapolis, Indiana, for its new global headquarters, a move designed to enhance operational efficiency following its acquisition of Bayer's animal health business. The state has provided a competitive incentive package involving retention of 1,600 jobs and the creation of over 570 new jobs in the next decade. The $100M campus is expected to yield cost savings and improve cash flow. Elanco aims to further its Innovation, Portfolio, and Productivity strategy while contributing positively to the local community and economy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.62%
Tags
none
-
Rhea-AI Summary

Elanco Animal Health (NYSE: ELAN) will host a virtual investor day on December 15, 2020, beginning at 10:00 AM ET. Presentations will be led by CEO Jeff Simmons and other executives, focusing on strategies for long-term shareholder value and 2021 financial guidance. The event will include a live Q&A session. Interested parties can register via the investor website, and a replay will be available for one year following the event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.18%
Tags
conferences
Rhea-AI Summary

Elanco Animal Health announced a public offering of 54,500,000 shares of its common stock at $30.25 per share, solely held by Bayer World Investments B.V. Bayer has granted underwriters an option to purchase an additional 8,175,000 shares. Elanco will not issue any shares nor receive proceeds from this offering, which is set to close around December 3, 2020. The offering will proceed under Elanco's existing registration statement with the SEC, with BofA Securities, Goldman Sachs, and Credit Suisse serving as joint book-running managers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.18%
Tags
-
Rhea-AI Summary

Elanco Animal Health announced a public offering of 54,500,000 shares of common stock, solely from Bayer World Investments B.V., an affiliate of Bayer AG, with an additional option for underwriters to purchase 8,175,000 shares. Elanco will not receive any proceeds from this sale, which is part of Bayer's divestment following its acquisition of Elanco's animal health business in 2020. The offering will utilize Elanco’s existing registration statement on Form S-3, with management by BofA Securities, Goldman Sachs, and Credit Suisse.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.33%
Tags
-
Rhea-AI Summary

Elanco Animal Health (NYSE: ELAN) will participate in the 3rd Annual Evercore ISI Virtual HealthCONx Conference on December 1, 2020. CEO Jeff Simmons is scheduled for a virtual fireside chat at 1:00 p.m. ET. Investors can access the live audio webcast on the Events and Presentations section of Elanco's investor website, with a replay available for one year. Established nearly 70 years ago, Elanco focuses on innovation in animal health, delivering products to enhance the well-being of farm animals and pets while committing to sustainability and community impact.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.37%
Tags
conferences
Rhea-AI Summary

Elanco Animal Health (NYSE: ELAN) reported Q3 2020 financial results, highlighting a 15% revenue increase to $889.6 million, bolstered by the Bayer Animal Health acquisition. Despite this, the company faced a net loss of $135 million due to rising operating costs associated with integration. Elanco plans to realize $275-$300 million in cost synergies by mid-2022, alongside significant restructuring measures affecting 900 positions. The company also received key product approvals, enhancing its Farm Animal portfolio, while adjusting Q4 2020 revenue guidance between $1,020 and $1,060 million, amid ongoing pandemic headwinds.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.03%
Tags
none

FAQ

What is the current stock price of Elanco Animal Health Incorporated (ELAN)?

The current stock price of Elanco Animal Health Incorporated (ELAN) is $11.86 as of December 23, 2024.

What is the market cap of Elanco Animal Health Incorporated (ELAN)?

The market cap of Elanco Animal Health Incorporated (ELAN) is approximately 5.8B.

What is Elanco Animal Health's core mission?

Elanco's core mission is encapsulated in their vision: 'Food and Companionship Enriching Life,' which they pursue by enhancing food security, improving pet health, and elevating food safety standards globally.

In how many countries does Elanco operate?

Elanco operates in over 90 countries worldwide.

What recent collaborations has Elanco engaged in?

Elanco recently collaborated with Agtech company Cattler to provide data-driven solutions to cattle farmers through services like Benchmark™ and Experior™.

What is the significance of Elanco's partnership with Athian?

The partnership with Athian aims to create a livestock carbon insetting marketplace, reducing greenhouse gas emissions and promoting sustainable farming practices.

What are some of Elanco's notable products?

Elanco's notable products include Seresto®, Experior™, and Bovaer®, the latter being a methane-reducing feed ingredient for cattle.

How is Elanco addressing sustainability in animal farming?

Elanco addresses sustainability through innovative products like Bovaer®, which reduces methane emissions from cattle, and partnerships aimed at creating carbon insetting marketplaces.

What financial goals has Elanco set for 2024?

Elanco expects constant currency revenue growth of 2% to 3% for 2024, driven by new product launches and operational improvements. They also anticipate significant debt reduction through strategic divestitures.

How does Elanco contribute to food safety?

Elanco contributes to food safety by developing products that improve the health and performance of farm animals, thereby ensuring a safer and more reliable food supply.

What is Elanco's approach to innovation?

Elanco's approach to innovation involves continuous R&D investments, strategic partnerships, and the development of new products that address pressing issues in animal health and sustainability.

How does Elanco support the health and wellness of pets?

Elanco supports pet health through an extensive range of veterinary products designed to improve the quality and longevity of pets' lives.

Elanco Animal Health Incorporated

NYSE:ELAN

ELAN Rankings

ELAN Stock Data

5.80B
490.44M
0.71%
98.94%
3.07%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
GREENFIELD